27 August 2020 | News
The company is already working with a number of UK partners and is forecasting compound growth nearly 30% of the next three years.
Image source: Shutterstock.com
Belgium based Europital, the global provider of medical management services for clinical research and drug development recently announced that it is opening a UK site to further expand its services to the UK biotech industry. The company is already working with a number of UK partners and is forecasting compound growth by nearly 30 per cent of the next three years.
The Europital site will expand out its operational team over the next few months and will target working with small and medium biotechs to design & execute projects, particularly for First in Man, Phase I and Phase II clinical studies.
Dr Mohamed El Malt, CEO and Chief Medical Officer of Europital commented, “We already partner with several biotechs in the UK and what we have seen is that there is a clear gap in the market for small innovators looking for a science focussed CRO that can provide the detailed knowledge and therapeutic experience. Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. What they need is a partner to bring a medical department with real-world trial experience to implement study design and protocols and be a scientific driving force behind the project’s success.”
Europital is planning to quickly expand its offering and will focus on providing expertise to partners in complex oncology indications, inflammatory diseases, immunology & infectious diseases studies. The UK site opening will be used to leverage the company’s phase iii experience with clinical studies directly conducted at UK investigative sites.